Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20020082299 A1
Publication typeApplication
Application numberUS 09/446,865
PCT numberPCT/CH1998/000273
Publication dateJun 27, 2002
Filing dateJun 23, 1998
Priority dateJun 25, 1997
Also published asUS6433015, WO1999000122A1
Publication number09446865, 446865, PCT/1998/273, PCT/CH/1998/000273, PCT/CH/1998/00273, PCT/CH/98/000273, PCT/CH/98/00273, PCT/CH1998/000273, PCT/CH1998/00273, PCT/CH1998000273, PCT/CH199800273, PCT/CH98/000273, PCT/CH98/00273, PCT/CH98000273, PCT/CH9800273, US 2002/0082299 A1, US 2002/082299 A1, US 20020082299 A1, US 20020082299A1, US 2002082299 A1, US 2002082299A1, US-A1-20020082299, US-A1-2002082299, US2002/0082299A1, US2002/082299A1, US20020082299 A1, US20020082299A1, US2002082299 A1, US2002082299A1
InventorsHans Meyer
Original AssigneeHans Meyer
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Method for reducing body weight
US 20020082299 A1
Abstract
The invention relates to a method for reducing the body weight of overweight persons and domestic pets by administering between 0.15 mg and 15 mg of creatine per kilogram of body weight per day. The invention also relates to the use of creatine for the production of a medicinal product to be used with said method.
Images(4)
Previous page
Next page
Claims(6)
1. Process for reduction of the body weight of overweight persons and domestic animals, characterized in that the overweight persons or domestic animals are administered creatine in a daily dosage of from 0,15 mg/kg to 15,0 mg/kg body weight.
2. Process according to claim 1, characterized in that creatine is administered in a daily dosage of from 1 mg/kg to 5 mg/kg body weight.
3. Process according to claim 1, characterized in that creatine is administered in a daily dosage of 1,5 mg/kg body weight.
4. Process according to one of claims 1 to 3, characterized in that creatine is administered in the form of creatine phosphate.
5. Use of creatine for the manufacture of a medicament for use in a process according to one of claims 1 to 4.
6. Use of creatine according to claim 5, characterized in that creatine is mixed with physiologically acceptable auxiliary substances in a manner known per se and brought into an administration form suitable for the use by pressing, granulating or filling into capsules.
Description
  • [0001]
    The present invention concerns a process for reduction of the body weight of overweight humans and domestic animals by administration of creatine as well as the use of creatine for the manufacture of a medicament for use in this process.
  • [0002]
    Overweight of humans and domestic animals is very common today, particularly in industrial countries. For instance, in the industrial countries, every second to third person is overweight. Overweight constitutes a considerable health hazard and very often leads to secondary diseases such as high blood pressure, arteriosclerosis, diabetes and diseases of the joints. The treatment with medicaments such as appetite depressants is very often accompanied by health hazards and unpleasant side effects and therefore unsatisfactory. There is therefore a need for a process with which the desirable weight reduction can be attained without the side effects and hazards connected with the use of centrally active appetite depressants.
  • [0003]
    Creatine [N-Amidinosarcosine; N-Carbamimidoyl -N-methylglycine; N-Aminoiminomethyl-N-methylglycine] is a natural substance predominantly present in muscle tissue of the vertebrates. Minor amounts are contained in the blood and brain. In the muscle, the greater part of creatine is present as creatine phosphate. Creatine phosphate plays an important role in the muscle as energy storage. In the working muscle, creatine phosphate with adenosine diphosphate (ADP) under the influence of the enzyme creatine kinase yields adenosine triphosphate (ATP) and creatine. In the resting muscle the reaction proceeds in the reverse direction. Intensive muscle contractions lead to exhaustion of the creatine phosphate depots and therewith to the known conditions of fatigue. Creatine is not synthesized in the muscle, it is transported into the muscle via the blood stream, partly after synthesis in the liver and pancreas and back resorption in the kidney, partly after food intake. Creatine is excreted via the kidney as creatinine.
  • [0004]
    From WO 94/02127 it is known that administration of creatine in a daily dosage of at least 15 g to 30 g, corresponding to 0,2 g to 0,4 g per kilogram of the body weight, in physically active test persons, e.g. athletes, leads to an enhancement of body weight, wich results from an increase of muscle mass. The same effect of creatine is described by R. Sahelian in “Creatine, Nature's Muscle Builder”, page 28, Avery Publishing Group, New York (1997) and by G. Gremion in the publication “Läufer” (1995), 8, pages 39-40. In these publications is additionally mentioned that beside an increase of the muscle mass the fat mass is decreased, but finally always an increase of body weight results.
  • [0005]
    However, the influence on body weight through creatine in the sense of a weight increase depending on an increase of muscle mass with simultaneous reduction of fat mass described in the above literature, only appears together with simultaneous high muscle strain, i.e. e.g. in athletes who are in tough performance training. An influencing of body weight by taking creatine without simultaneous strong muscular strain has hitherto not been described.
  • [0006]
    It has now been found that the body weight of overweight persons and overweight domestic animals can be reduced by administering a daily dosage of 0,15 mg to 15 mg of creatine per kilogram body weight.
  • [0007]
    Subject of the present invention is therefore a process for reduction of the body weight of overweight persons and overweight domestic animals which is characterized in that the overweight persons and overweight domestic animals are administered daily 0,15 mg to 15 mg of creatine per kilogram body weight. This dosage corresponds in a person of about 70 kg body weight the intake of 10 mg to 1000 mg of creatine per day. Preferably the daily dosage amounts to 1 mg to 5 mg of creatine per kilogram body weight or in a person of about 70 kg body weight correspondingly daily 50 mg to 300 mg of creatine. Particularly preferred is a daily dosage of creatine of 1,5 mg/kg body weight, corresponding to 100 mg of creatine daily in person with a body weight of about 70 kg. The daily dosage of creatine is preferably taken as a single dose in the morning, but it can also be divided up in two or more partial dosages.
  • [0008]
    The expression creatine used in the present description also comprises creatine phosphate.
  • [0009]
    As domestic animals in particular cats and dogs come into consideration.
  • [0010]
    A further subject of the present invention is the use of creatine in a process for the manufacture of a medicament for use in a process for reduction of the body weight of overweight persons and domestic animals, which is characterized in that the overweight persons and domestic animals are administered a daily dosage of 0,15 mg to 15 mg of creatine per kilogram body weight.
  • [0011]
    According to one embodiment of the present invention creatine can also be used in combination with vitamins, trace elements and/or electrolytes. As vitamins all fat- and water-soluble vitamins are suitable. Suitable trace elements are for example iron, fluorine, iodine, copper, lithium, manganese, molybdenum, nickel, selenium, silicium, vanadium, tin and zinc. Suitable electrolytes are for example electrolytes of the water balance such as Na+, K+Mg2+, Ca2+, Mn2+, Zn2+, Cl, SO4 2− and PO4 3−.
  • [0012]
    Moreover, creatine can also be combined with other slimming agents (antiadipositas).
  • [0013]
    Since creatine is an endogenic substance, no side effects appear in the low dosages employed according to the invention and patient compliance is therefore excellent. A considerable advantage of the process of the invention for reduction of the body weight consists in the fact that the eating habits can be maintained and that daily only one tablet has to be taken.
  • [0014]
    The use of creatine for the manufacture of medicaments according to the invention comprises its addition into all administration forms suitable for the above mentioned field of use. Such administration forms are e.g. tablets, dragees, capsules or other solid medicaments disintegrating in the gastric juice, mono- or multilayered solid medicaments ensuring a delayed or stepwise release of the active ingredient, pellets in capsules or pressed with immediate or delayed release, solid medicaments resistant to gastric juice, solutions or suspensions of the active substance in soft gelatine capsules or hard gelatine capsules or other wrappings sealed according to specific methods, forms soluble or suspendible in water or other beverages such as e.g. effervescent tablets, effervescent granulates, soluble tablets and soluble granulates, liquid medicaments such as drops or syrups for taking as concentrate or diluted in water or other beverages, preparations for transdermal application such as e.g. plasters, gels, creams and salves, liquid administration forms for injection and infusion, suppositories for rectal application.
  • [0015]
    Preferred are solid administration forms such as tablets, dragees, capsules, granulates, suppositories and liquid forms such as solutions or suspensions.
  • [0016]
    In overweight domestic animals the oral administration forms are preferably mixed with the feed or the drinking water.
  • [0017]
    The manufacture of the medicament is characterized in that creatine is mixed with physiologically acceptable auxiliary substances in a manner known per se and brought into an administration form suitable for the use by pressing, granulating, filling into capsules or adding to salve bases.
  • [0018]
    In the manufacture of the medicament conventional processes for admixture, granulation, drageeing, dissolution or lyophilization can be employed.
  • [0019]
    Medicaments for oral use are obtained e.g. by combining the active ingredient with solid carrier substances, the mixture obtained is, if desired, granulated and the mixture or granulate is, if desired or necessary, after the addition of suitable auxiliary substances, processed to tablets or dragee cores.
  • [0020]
    Suitable carrier substances are in particular filling substances such as sugars, e.g. lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, e.g. tricalcium phosphate or calcium hydrogen phosphate, moreover thickening agents such as starch paste using e.g. maize-, wheat-, rice- or potatostarch, gelatine, tragacanth gum, methyl cellulose, hydroxypropylmethyl cellulose, sodium carboxy methyl cellulose and/or polyvinyl pyrrolidone and/or, if desired, disintegrating agents such as the above mentioned starches, moreover carboxymethyl starch, cross-meshed polyvinyl pyrrolidone, agar, alginic acid or a salt thereof, such as sodium alginate. As auxiliary agents primarily flow regulation agents and lubricants are suitable such as e.g. silicic acid, silicone dioxide, talcum, stearic acid or salts thereof such as magnesium or calcium stearate and/or polyethylene glycol.
  • [0021]
    Further orally useful medicaments are hard, two-piece gelatine capsules as well as soft closed capsules made of gelatine and a softener such as glycerol or sorbitol. The hard capsules can contain the active ingredient in the form of a granulate, for instance in admixture with filling substances such as lactose, thickening agents such as starches and/or flowing agents such as talcum or magnesium stearate and, if desired, stabilizing agents. In soft capsules the active substance is preferably dissolved or dispersed in suitable liquids such as fatty oils, paraffin oil or liquid polyethylene glycol, stabilizing agents optionally being added.
  • [0022]
    For parenteral administration primarily aqueous solutions are useful, moreover suspensions of the active substance, such as corresponding oily injection suspensions; suitable lipophilic solvents or vehicles being used, such as fatty oils, e.g. sesame oil, or fatty acid esters, such as e.g. ethyl oleate or triglycerides, or aqueous injection suspensions which contain viscosity increasing substances, e.g. sodium carboxymethyl cellulose, sorbitol and/or dextrane and optionally also stabilizing agents.
  • [0023]
    The contents of active ingredient in the medicament can e.g. amount to from 0,1 to 99 per cent by weight of the preparation, preferably 1 to 90 per cent by weight.
  • [0024]
    The present invention is illustrated further by the following examples.
  • [0025]
    [Creatine-monohydrate (Chemie Linz, A), Avicel PH 102 (microcrystalline cellulose; FMC Corp.), Explotab (sodium starch glycolate; Mendell, Patterson, N.Y.), Kollidon K30 (polyvinyl pyrrolidone or polyvidone or PVP; BASF, U.K.), Syloid 244 (silica gel; W.R. Grace/Davison Chemical Div., Baltimore), Cutina HR (wax mixture, ethoxylated esters; Henkel) are commercial products.]
  • EXAMPLE 1
  • [0026]
    [0026]
    Tablets containing 100 mg of
    creatine can be manufactured as follows:
    Composition for 1 tablet 1000 tablets
    Creatine monohydrate 100.00 mg  100.00 g 
    Avicel PH 102 17.20 mg  17.20 g 
    Explotab 10.12 mg  10.12 g 
    Kollidon K30 6.00 mg 6.00 g
    Syloid 244 0.64 mg 0.64 g
    Cutina HR 1.04 mg 1.04 g
  • [0027]
    Creatine, Avicel and Explotab are homogenously mixed within ten minutes, rubbed through a sieve (710 μm) and mixed agein. The Kollidon is added as 20 percent solution, the mixture well mixed and subsequently rubbed through a sieve (710 μm). The moist granulate is dried 5 hours at 45° C. in a drying cabinet and sieved again (710 μm). Syloid and Cutina are homogenously mixed, sieved (710 μm) and homogenously mixed with the dry granulate. The finished granulate is pressed to tablets on the tabletting machine with a stamp of 6 mm diameter. (Tablet weight: 135 mg).
  • EXAMPLE 2
  • [0028]
    Granulate
  • [0029]
    A granulate containing 1,0 g of creatine per 1,33 g of granulate can be manufactured as follows:
    Composition for 1330 g of granulate:
    Creatine 1000 g 
    Avicel PH 102 170 g
    Explotab 100 g
    Kollidon K30  60 g
  • [0030]
    Creatine, Avicel and Explotab are homogenously mixed for 10 minutes, rubbed through a sieve (710 μm) and mixed again. After the addition of the Kollidon as 20 percent aquid solution the mixture is well stirred and subsequently rubbed through a sieve (710 μm). The moist granulate obtained is dried 5 hours at 45° C. in a drying cabinet and sieved agein (710 μm).
  • [0031]
    Use example:
  • [0032]
    An experiment was carried out with 22 test persons in order to confirm the weight reducing effect of creatine using the dosage according to the invention. The test persons were instructed for the duration of the experiment not to change their day-to-day habits (diet and physical exercise). In order to find the optimal dosage the test persons were initially divided into three groups with a daily dosage of either 100 mg, 300 mg or 600 mg of creatine. After 3 months the group with 100 mg had shown the most noticeable weight loss, whence the dosage was reduced in all test persons to a single dose of 100 mg. The results of the 7-month study are summarized in the following diagram. They demonstrate that after the 3 months dosage-finding period a steady decrease of body weight occured. The data are reported as so-called body mass index (BMI), which is calculated from the body weight in dilograms divided by the height in meters in square.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US7838026Oct 28, 2003Nov 23, 2010Mcneil-Ppc, Inc.Burst-release polymer composition and dosage forms comprising the same
US7968120Sep 28, 2002Jun 28, 2011Mcneil-Ppc, Inc.Modified release dosage forms
US7972624Feb 24, 2009Jul 5, 2011Shun-Por LiMethod of manufacturing modified release dosage forms
US8114328Aug 4, 2004Feb 14, 2012Mcneil-Ppc, Inc.Method of coating a dosage form comprising a first medicant
US8545887Sep 28, 2002Oct 1, 2013Mcneil-Ppc, Inc.Modified release dosage forms
US8673190Dec 7, 2011Mar 18, 2014Mcneil-Ppc, Inc.Method for manufacturing dosage forms
US8673352Apr 15, 2005Mar 18, 2014Mcneil-Ppc, Inc.Modified release dosage form
US20030068373 *Sep 28, 2001Apr 10, 2003Joseph LuberImmediate release tablet
US20040213849 *Sep 28, 2002Oct 28, 2004Sowden Harry S.Modified release dosage forms
US20040241208 *Sep 28, 2002Dec 2, 2004Sowden Harry S.Fondant-based pharmaceutical composition
US20050019407 *Sep 28, 2002Jan 27, 2005Sowden Harry S.Composite dosage forms
US20050266084 *Sep 28, 2002Dec 1, 2005Shun-Por LiModified release dosage forms
Classifications
U.S. Classification514/565
International ClassificationA61P3/04, A61K31/195, A61K9/48, A61K31/198
Cooperative ClassificationA61K31/198
European ClassificationA61K31/198
Legal Events
DateCodeEventDescription
Apr 19, 2000ASAssignment
Owner name: IPR-INSTITUTE FOR PHARMACEUTICAL RESEARCH AG, SWIT
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEYER, HANS;REEL/FRAME:010753/0518
Effective date: 19991216
Jul 16, 2003ASAssignment
Owner name: BIOEQUAL AG, SWITZERLAND
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:IPR INSTITUTE FOR PHARMACEUTICAL RESEARCH AG;REEL/FRAME:014268/0625
Effective date: 20030619
Feb 10, 2006FPAYFee payment
Year of fee payment: 4
Mar 22, 2010REMIMaintenance fee reminder mailed
Jun 30, 2010SULPSurcharge for late payment
Year of fee payment: 7
Jun 30, 2010FPAYFee payment
Year of fee payment: 8
Jan 9, 2014FPAYFee payment
Year of fee payment: 12